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Paediatric global antibiotic guidelines are inconsistent, most likely due to the limited pharma-
cokinetic and efficacy data in this population. We investigated factors underlying variation in
antibiotic dosing using data from five global point prevalence surveys.
Methods & findings
Data from 3,367 doses of the 16 most frequent intravenous antibiotics administered to chil-
dren 1 month–12 years across 23 countries were analysed. For each antibiotic, we identified
standard doses given as either weight-based doses (in mg/kg/day) or fixed daily doses (in
mg/day), and investigated the pattern of dosing using each strategy. Factors underlying
observed variation in weight-based doses were investigated using linear mixed effects mod-
els. Weight-based dosing (in mg/kg/day) clustered around a small number of peaks, and all
antibiotics had 1–3 standard weight-based doses used in 5%-48% of doses. Dosing strategy
was more often weight-based than fixed daily dosing for all antibiotics apart from teicoplanin,
which had approximately equal proportions of dosing attributable to each strategy. No
strong consistent patterns emerged to explain the historical variation in actual weight-based
doses used apart from higher dosing seen in central nervous system infections, and lower in
skin and soft tissue infections compared to lower respiratory tract infections. Higher dosing
was noted in the Americas compared to the European region.
Conclusions
Antibiotic dosing in children clusters around a small number of doses, although variation
remains. There is a clear opportunity for the clinical, scientific and public health communities
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to consolidate behind a consistent set of global antibiotic dosing guidelines to harmonise
current practice and prioritise future research.
Introduction
Paediatric antibiotic dosing guidelines in children are inconsistent, at both international and
national levels [1, 2], most likely due to the lack of pharmacokinetic/pharmacodynamic
(PKPD) data in this population [1]. Large differences in the choice of antibiotic prescribed for
the same indication have been observed in both children and neonates [3–5] between coun-
tries [6, 7], between hospitals within a country [8] and between doctors within a single hospital
[9]. However, despite differences in PK, leading to different optimal doses in children com-
pared to adults [10], and critically ill children compared to well children [11], little attention to
date has been focused on quantifying the differences and identifying the factors underlying the
variation observed in dosing.
Optimal dosing of antibiotics in children differs due to PKPD factors such as age, weight,
or comorbidities of the individual, the therapeutic index or PKPD target parameter of the anti-
biotic, and species, site of infection, or resistance profile (both phenotyped and anticipated
from local knowledge) of the organism [10]. Antibiotic dosing decisions may be based on
either fixed daily doses (FDD), commonly split into age or weight bands, often in mg/day, or
actual weight-based doses (WBD), often in mg/kg/day [12]. Studies in the UK and France have
found substantial variation in vancomycin and gentamicin dosing practice in neonates [13,
14], a European study identified marked variation in WBD in children in two antibiotics [12],
and a study in Pakistan found that less than 40% of children were receiving rational dosing for
antibiotics prescribed in hospital [15]. Very few studies have attempted to identify the factors
underlying clinicians’ decisions to use specific doses and strategies. Here we used data from
five global point prevalence surveys to investigate variation in dosing for 16 antibiotics given
intravenously in hospital for treatment in children. We investigate the frequency of adminis-
tration, examine whether dosing strategy is guided by FDD or WBD, and aim to identify evi-
dence for specific factors underlying variation in dosing.
Methods
Data was obtained from five PPS surveys in the Global Antimicrobial Resistance, Prescribing
and Efficacy in Neonates and Children (GARPEC) study. Detailed methods have been
described elsewhere [7]. Briefly, one 1-day pilot PPS was carried out over 2 months in 2015
and four full-scale 1-day PPSs were conducted between February 2016 and February 2017:
February-March 2016 (1st PPS), May-June 2016 (2nd PPS), September-October 2016 (3rd PPS),
and December 2016-February 2017 (4th PPS). The details of antibiotic prescription (drug,
dose, route of administration), indication (targeted or empiric) and demographic data (e.g.
sex, body weight), clinical indications and comorbidities (except in 65 of 162 children from
the Pilot PPS) were collected. Patients within each PPS survey were anonymised with a unique
identifier allowing identification of children receiving multiple antibiotics in the same survey.
Age was recorded in months until 60 months and in years, thereafter; gestational age at birth
was not captured. Data were collected between March 2015 and February 2017 and were fully
anonymised before access for analysis. The PPS surveys were conducted as clinical audit and
not routine health surveillance or research as the survey involved no interventions or experi-
mentation; St George’s University of London Research Ethics Committee provided
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confirmation that ethical approval was not required for the initial survey (ARPEC) on which
the PPS surveys were based. Consequently, formal ethical approval and/or written informed
consent was not required in many of the 65 hospitals and no central ethical approval was
obtained or Clinical Audit Facilitator was consulted. It was the responsibility of each of the
participating hospitals received local ethics approval if required. The authors were not involved
in local data collection and so did not access identifying patient information at any time. The
data collection was carried out by local participating sites and they voluntarily contributed
their data to GARPEC network.
Data preparation
Data consisted of intravenous doses (recorded as parenteral in pilot PPS) given for treatment
and not prophylaxis or decolonisation to hospitalised children with recorded age 1 month– 12
years old (as per Standards for Research (StaR) in Child Health project [16]) and where weight
and sex was also recorded. We focused on the mostly frequently prescribed 16 of 76 antibiotics,
each with at least 75 doses recorded, comprising 83% of all IV doses. Observations where the
absolute value of WHO weight-for-age z-scores [16] was greater than eight standard deviations
from the mean from 21 individuals up to 10 years old were excluded as likely data processing
errors. For children aged 11–12 years, weights for six children outside 2.5 and 97.5 percentiles
were replaced by the respective percentile values as height data was not available, and is
required, to calculate weight z-scores for these older children. A further 2.9% of doses were
excluded as extreme outliers (details in S1 Appendix and S1 and S2 Tables) and five doses
recorded as less than once per day (e.g. every 36h) were counted as once per day.
Analysis of dosing strategy
Dosing was analysed using two different metrics–fixed daily dose (FDD), in mg per day, and
weight-based dose (WBD), in mg per kg per day, where WBD is equal to FDD divided by the
child’s weight in kg. Doses were assigned to being either consistent with ‘standard FDD’ only,
consistent with ‘standard WBD’ only, consistent with ‘both standard FDD and WBD’ or con-
sistent with ‘neither’.
‘Standard FDDs’ were defined as doses given to at least 5% of children receiving each anti-
biotic, with the cut-off of 5% chosen following inspection of the frequency plot of doses. Stan-
dard FDDs were then compared to standard vial sizes from EMC [17] and BNFc [18].
‘Standard WBDs’ was less straightforward to define as the actual dose given to children may
have been rounded to a dose in mg for more convenient administration. We could not assign
standard WBDs statistically for each antibiotic using mixture models, as the models did not
generally converge. Instead, WBD doses, in mg/kg/day, were rounded to the nearest whole
number, apart from gentamicin, which was rounded to one decimal place. The top 10 WBDs
for each antibiotic were then identified, including WBDs within 1% of the top WBDs as being
associated with that WBD; this was done sequentially so that each dose was assigned to one
standard WBD only. The top dose for metronidazole was taken to be 22.5mg/kg/day as this is
commonly recommended [18–21]. As with FDD, frequency plots were used to determine the
cut-off value for WBD, which was also 5%. WBD were compared to dosing recommendations
for common indications from six sources—the USA ‘Red Book’ [19], the European ‘Blue Book
[20], the British National Formulary for children (BNFc) [18], the Indian National Centre for
Disease Control [21], the WHO Pocket Book of Hospital Care in Children [22], and the sum-
mary of product characteristics (SPC) [17]. Guideline values for IV treatment were extracted
from Mathur et al 2020 [23], except cefepime and teicoplanin, which were taken from the
source documents, and SPCs which were obtained from the electronic medicines
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compendium (EMC) website. To determine if some of the highest WBD doses were due to
premature babies over one month of age we also plotted WBD for children over four months
old (81% of doses), when all babies are expected to have a gestational age of at least 40 weeks.
Analysis of factors underlying variation in WBD
Factors underling variation in WBD (mg/kg/day) were analysed truncating WBD for each
antibiotic at its 2.5% and 97.5% percentiles to avoid undue influence from outliers, and using a
Box-Cox transformation to achieve approximate normality (lambda = 0.109), which was then
mean-centred for each antibiotic to facilitate comparison. No individual patient clinical data
was available from these single day PPS. Within-individual explanatory fixed-effect variables
included the top nine clinical indications for treatment above category ‘other’ (88% of doses);
empiric (awaiting culture or no culture taken) or targeted (pathogen or resistance profile
known) therapy; presence of comorbidities (none, renal, liver and other); and markers of likely
serious infection such as ventilation status (no/non-invasive ventilation grouped vs invasive
ventilation), taking other antibiotics (binary) and taking other drugs apart from antibiotics
(binary). Grouping of predictor variables was determined based on prevalence of factors and
consultation with a clinical (NR). Analyses were restricted to complete cases for explanatory
variables (see Table 1 for numbers included in model). The correlation between weight and
age was high (0.88) and so only age was included as it was not a component of the response
variable. Age was centred on the median value and fitted including linear and quadratic terms
and presented in units of 5 years for clarity.
We fitted the same linear mixed effects model for each antibiotic separately with indepen-
dent between-individual random effects of country and hospital using the lme4 package [24]
Table 1. Patient characteristics split by antibiotic.








% infant, toddler, early
childhood, middle
childhood
% WHO Region Africa, Americas,
Europe, South-East Asia, Western
Pacific
Amikacin 254 198 24 (7, 60) 13 (10) FN/ Fever (20%) 36%, 10%, 30%, 24% 5%, 37%, 38%, 19%, 2%
Ampicillin 158 122 16 (3, 48) 13 (11) Bac LRTI (46%) 48%, 12%, 20%, 20% 20%, 44%, 20%, 4%, 13%
Cefepime 196 175 24 (8, 60) 13 (8) FN/ Fever (26%) 34%, 13%, 30%, 23% 1%, 89%, 5%, 0%, 6%
Cefotaxime 170 133 13 (3, 48) 11 (9) Sepsis (29%) 49%, 9%, 26%, 15% 2%, 5%, 54%, 24%, 15%
Ceftazidime 103 86 36 (15, 72) 16 (9) Bac LRTI (40%) 18%, 14%, 36%, 32% 1%, 22%, 57%, 15%, 5%
Ceftriaxone 472 352 24 (8, 60) 14 (10) Bac LRTI (31%) 35%, 15%, 28%, 22% 7%, 26%, 36%, 24%, 6%
Cefuroxime 92 60 24 (11, 60) 16 (12) Bac LRTI (32%) 30%, 15%, 30%, 24% 1%, 21%, 77%, 1%, 0%
Ciprofloxacin 74 61 36 (13, 96) 16 (11) Sepsis (30%) 26%, 7%, 31%, 36% 0%, 32%, 50%, 15%, 3%
Clindamycin 109 78 36 (19, 84) 20 (12) SSTI (32%) 18%, 11%, 37%, 34% 1%, 51%, 39%, 3%, 6%
Co-amoxiclav 263 198 24 (9, 60) 14 (10) Bac LRTI (53%) 35%, 14%, 31%, 21% 3%, 28%, 43%, 23%, 3%
Gentamicin 215 180 20 (4, 72) 15 (13) Bac LRTI (21%) 45%, 8%, 19%, 28% 17%, 13%, 54%, 3%, 13%
Meropenem 397 336 18 (6, 48) 12 (9) Sepsis (32%) 44%, 11%, 25%, 20% 7%, 27%, 44%, 21%, 2%
Metronidazole 132 93 60 (24, 96) 19 (12) Surgical Dis (34%) 20%, 5%, 36%, 40% 5%, 27%, 48%, 16%, 5%
Pip-taz 287 233 36 (14, 84) 17 (12) FN/ Fever (37%) 23%, 13%, 34%, 30% 3%, 15%, 68%, 10%, 5%
Teicoplanin 83 59 48 (12, 90) 18 (13) FN/ Fever (41%) 25%, 7%, 30%, 37% 0%, 14%, 82%, 1%, 2%
Vancomycin 362 294 16 (5, 48) 12 (9) Sepsis (27%) 42%, 16%, 24%, 18% 4%, 47%, 33%, 8%, 8%
Bac LRTI: Bacterial lower respiratory tract infection, CNS: central nervous system infection; CRBSI: catheter related blood stream infection; FN: febrile neutropenia;
GUTI: gastro-intestinal tract infections; SSTI: skin and soft tissue infections; Dis: disease; UTI: urinary tract infection; Infant: 1–12 months; Toddler 13–23 months;
Early childhood: 2–5 years; Middle childhood: 6–11 years.
https://doi.org/10.1371/journal.pone.0252223.t001
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in R [25]. Box-Cox transformations used MASS package [26], significance testing of individual
factor levels used Satterthwaite approximations from the lmerTest package [27], and 95% con-
fidence intervals were obtained using the model-outputted t-statistic and degrees of freedom.
Data used for analyses is available in S1 Data.
Results
Data consisted of 3,367 doses from 2,463 children in 65 hospitals in 23 countries. Almost half
(43%) of doses were from the WHO European Region, 31% the Americas, 14% South-East
Asia, 6% Western Pacific Region and 5% African Region; none were from Eastern Mediterra-
nean Region (Table 1). The median age of children was 24 months (IQR: 7–60 months, Range:
1 month–11 years) and 35% of doses were given to children under one year of age. The median
weight of children was 11kg (IQR: 6.5–19.0 kg, Range: 0.74–64.8kg). Just over half of doses
(54%) were given to boys.
Frequency
Drugs varied considerably in the frequency of administration per day (Fig 1A and S3 Table).
Amikacin, gentamicin and teicoplanin were predominantly (but not exclusively) given once
per day whereas ampicillin and vancomycin were predominantly given 4 times per day. Ten of
the 16 antibiotics had a clear main frequency given in at least 80% of doses. Three antibiotics
(ceftriaxone, clindamycin, and piperacillin-tazobactam) had two common frequencies each
given in approximately half of doses, and the remaining three antibiotics (cefotaxime, cipro-
floxacin and vancomycin) had a predominant frequency given in between 60% and 65% of
doses. Restricting data to children over four months (S1 Fig) removed some of the frequencies
given to small numbers of children but they broad patterns remained the same.
Dosing strategy
WBD clustered around a small number of peaks, and all antibiotics had between one and three
standard WBDs used in at least 5% of doses (Fig 2 and S4 Table). Cefepime had the highest
proportion of doses consistent with dosing by standard WBD, although this still only occurred
in under half of doses (48%) with all of these doses being within 1% of 150mg/kg/day. Genta-
micin, piperacillin-tazobactam and teicoplanin all had under 25% of doses consistent with dos-
ing by standard WBD. Overall, 84% of doses were within the minimum and maximum values
from the different guidelines and SPC. The antibiotic with the lowest percentage of doses
within guideline ranges was vancomycin (46%), while the highest was ampicillin (99%).
Restricting data to children over four months removed some of the extremely high WBD in
amikacin, cefepime and teicoplanin but the broad patterns remained similar (S2 Fig).
Eleven of 16 antibiotics had between one and three standard FDDs that were administered
in at least 5% of doses. Ceftriaxone and ciprofloxacin had the highest proportion of doses con-
sistent with standard FDD at 30% and 28%, respectively (Fig 3 and S5 Table). However, teico-
planin had the highest percentage of doses (11%) given as the same single FDD (400mg). Five
antibiotics (amikacin, cefepime, gentamicin, meropenem and piperacillin-tazobactam) had no
standard FDDs that that were administered in at least 5% of doses. Of the 26 standard FDDs,
16 (62%) could be attributed to children just being given between one and three full vials of
100mg, 200mg, 250mg, 300mg, 500mg, 600mg, 1g, and 2g, depending on the vial sizes avail-
able for each drug. Standard FDD that we could not attribute to a small number of full vials
were cefotaxime 1200mg, ceftazidime 3600mg, cefuroxime 1800mg and 4500mg, clindamycin
120mg, co-amoxiclav 600mg (perhaps 500mg amoxicillin and 100mg clavulanate), metronida-
zole 150mg and 600mg, teicoplanin 160mg and vancomycin 600mg.
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Fig 1. Frequency and dosing strategy by antibiotic. A. Frequency of antibiotic dosing within 24h. Antibiotics are ordered by most
common frequency–once per day at the top and 4 times per day at the bottom. Note that frequency once per day includes 5 doses
given less than once per day (e.g. every 36h). B. Dosing strategy for each antibiotic. Each dose was assigned to being consistent with
dosing by fixed daily dose (FDD), weight-based dose (WBD), both or neither. Antibiotics are sorted by the proportion assigned to a
dosing strategy.
https://doi.org/10.1371/journal.pone.0252223.g001
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Fig 2. Antibiotics showed between one and three peaks (coloured bars) consistent with dosing by standard WBD. Overlaid are guideline recommendations
for IV dosing in children, generally and for priority syndromes (severe infection, pneumonia, sepsis, acute otitis media, pharyngitis, urinary tract infection)
from five different guidelines: Blue Book (BlueBk), British National Formulary for children (BNFc), Indian National Centre for Disease Control (NCDC),
WHO pocket book (PktBk) and Red book (RedBk). Multiple entries for a single guideline indicate different frequencies of daily dosing, indications (e.g.
PLOS ONE Characterising paediatric antibiotic dosing variation
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The proportion of doses assigned to a dosing strategy (standard WBD and/or standard
FDD) varied considerably, from 23% for piperacillin-tazobactam to 61% for ceftriaxone FDD
(Fig 1B and S6 Table). Ceftriaxone, cefuroxime, ciprofloxacin, clindamycin and metronidazole
had over half of doses consistent with dosing by either WBD or FDD, whereas gentamicin,
meropenem, piperacillin-tazobactam and vancomycin all had less than of one third of doses
consistent with dosing by WBD. All drugs had a higher proportion of doses consistent with
WBD than FDD, apart from teicoplanin, which had approximately 25% of doses consistent
meningitis) or age/weight group of children. Lines denote recommended range, and dots denote recommended dose. Seven recommendations of fixed daily
doses (mainly for larger children) have been converted to relative daily doses. Bars coloured both gray and ranked are due to rounding used to produce graph.
https://doi.org/10.1371/journal.pone.0252223.g002
Fig 3. Antibiotics varied in their use of standard fixed doses (FDD). Black dots show doses in mg shared by at least 5% of children. Grey
dots show all other doses–the doses following diagonal lines are constant mg/kg/day.
https://doi.org/10.1371/journal.pone.0252223.g003
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with each strategy. All drugs had less than 15% of doses consistent with dosing by both WBD
and FDD.
Drugs varied in their pattern of dosing strategy of (standard WBD and/or standard FDD)
by both weight and age, although no clear patterns emerged (S3 and S4 Figs). For example,
cefepime dosing was broadly consistent across all weight and age bands; teicoplanin and ceftri-
axone showed increasing tendency towards dosing by FDD with increasing weight and age;
and metronidazole showed increasing tendency of dosing by WBD with increasing weight and
age.
Factors underlying variation in WBD
Models consisted of 2,658 doses across 16 antibiotics. The sample size in each model ranged
from 59 for Teicoplanin to 352 for Ceftriaxone (median 154; Table 1).
There were no strong consistent patterns in associations between factors and dosing across
antibiotics. Compared to bacterial lower respiratory tract infections, dosing was significantly
lower for patients with skin and soft tissue infections for four antibitoics (ceftazidime, co-
amoxiclav, meropenem and piperacillin-tazobactam), and significantly higher for patients
with central nervous system infections for three antibiotics (cefotaxime, meropenem, vanco-
mycin; Fig 4 and S7 Table), although amikacin was associated with significantly lower dosing
for the same diagnosis. Lower average WBD for children with renal comorbidities compared
to no morbidities was observed for cefepime, ceftazidime, meropenem and vancomycin. Three
antibiotics, cefotaxime, gentamicin and vancomycin, were associated with lower WBD in hos-
pital acquired infections compared to community acquired infections; vancomycin was also
associated with higher WBD when given targeted than empirically.
The statistical models showed strikingly different patterns in the variation remaining after
adjusting for the effects of the factors considered (S5 Fig and S8 Table). In particular, clinda-
mycin showed substantial proportions of variation due to country (42%) and hospital (34%).
In contrast, cefepime and teicoplanin showed no evidence of consistent variation between
countries or between hospitals.
Discussion
We characterised variation in antibiotic dosing for IV treatment in children using PPS data
from over three thousand prescriptions in 65 hospitals across 23 countries. Dosing predomi-
nantly clustered around a small number of strategies, although variation remained. There were
no clear association between the patterns of dosing and comorbidities, underlying disease, or
clinical infection severity, apart from some antibiotics having higher doses in central nervous
system infections, and lower doses in skin and soft tissue infections compared to lower respira-
tory tract infections (the most common indication).
The majority of antibiotics (10/16) had a common frequency of administration given in at
least 80% of doses that were broadly consistent with PKPD principles. For instance, the two
aminoglycosides, amikacin and gentamicin, were predominantly given once per day, consis-
tent with concentration-dependent killing, whereas cephalosporins and penicillins were pre-
dominantly given three or four times daily consistent with time-dependent killing [10].
Dosing strategy was attributable to weight-based dosing (WBD) more often than fixed daily
dosing (FDD, e.g. by age band) for all antibiotics apart from teicoplanin, which had approxi-
mately equal proportions of dosing attributable to each strategy. Dosing by weight, rather than
fixed daily doses (perhaps split by age), may reflect the predominance of weight-based dosing
in most international guidelines and enables fine-scale alterations to dosing, for example when
renal comorbidities are present. FDD may be more straightforward to administer by vial but
PLOS ONE Characterising paediatric antibiotic dosing variation
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Fig 4. Effect estimates and 95% confidence intervals of significant effects (p<0.05) from models of standardised WBD for the most common diagnoses.
Models were run separately for each antibiotic and contained the same fixed and random effects for each model. Reference levels for each factor were chosen as
the level with the highest proportion of doses (region: Europe, PPS: most recent survey (4th), diagnosis: bacterial LRTI, empiric: empiric, sex: male). CNS:
central nervous system infection; CRBSI: catheter related blood stream infection; FN: febrile neutropenia; GUTI: gastro-intestinal tract infections; SSTI: skin
and soft tissue infections; Dis: disease; UTI: urinary tract infection; HAI: hospital acquired infection; Vent: ventilation; ab: antibiotic; PPS: point prevalence
survey; SE: south-east; W: west.
https://doi.org/10.1371/journal.pone.0252223.g004
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risks over or under-dosing children, particularly those of extreme weight for age, potential
negative consequences in terms of efficacy, toxicity and antimicrobial resistance. Dosing in
WBD clustered around one to three standard doses for each antibiotic. These were broadly
consistent with one or more of the six current guidelines we examined, but not all, suggesting
that guidelines are taken into consideration when making dosing decisions, although compari-
sons are complicated as guidelines themselves show different levels of consistency for different
antibiotics. However, between approximately 40% and 80% of doses for each antibiotic were
not attributable to standard dosing by FDD or WBD. This may be due to use of local hospital
guidelines, perhaps reflected in the substantial residual country-to-country and hospital-to-
hospital variation estimates for some antibiotics after accounting for child-level characteristics,
or dosing decisions taken by individual prescribers.
Dosing was attributable to FDD in up to 30% of doses for each antibiotic. In theory, this
could be partly due to older, heavier children receiving adult doses, but we found no strong
evidence for this across antibiotics. Approximately 60% of FDDs could be attributed to simple
multiples of vial sizes, suggesting that dosing strategy could simply be reflecting vial sizes avail-
able at the point of prescription.
Variation in dosing might be expected due to varying PKPD properties in different clinical
scenarios, such as diagnosis, TDM (mainly amikacin, vancomycin and gentamicin) or varia-
tion in antibiotic susceptibility [10, 28]. Although this seemed to be the case for some drugs,
such as dosing relative to weight was higher for vancomycin in targeted therapy than empiric
therapy, the high proportion of vancomycin doses outside of guidelines, and higher dosing for
central nervous system infections than lower respiratory tract infections, we did not find evi-
dence of strong patterns across all antibiotics. The finding of lower WBD on average in hospi-
tal acquired infections compared to community acquired infections for cefotaxime,
gentamicin and vancomycin was curious and not easily explainable, emphasising the need for
closer attention to be paid to dosing of antibiotics in children.
This study has several limitations. Firstly, we did not have any data on loading doses, bolus,
short infusion, prolonged infusion, different doses on start or stop days, or TDM (expected to
affect only amikacin, vancomycin and gentamicin), which may be driving some of the differ-
ences observed. Secondly, gestational age was not captured and some extremely pre-term
babies may be receiving neonatal doses despite being at least one month old, although patterns
in data restricted to babies over four months old (at least term) did not differ substantially
from the full dataset. Thirdly, the statistical analyses used different numbers of observations
(between 59 and 352; median of 154) for each antibiotic, and a relatively large number of statis-
tical tests. Results should therefore be interpreted in this context and conclusions drawn on
broad patterns only. Finally, although the survey included 23 countries, not all WHO regions
were equally represented. Specifically, there were no data from Eastern Mediterranean Region
and almost half of doses came from European region. Although both Africa and Western
Pacific regions each accounted for approximately 5% of doses, both regions were relatively
well represented in ampicillin and gentamicin, with approximately 17% of doses from Africa
region and 13% of doses from Western Pacific region. Additionally, data came from four hos-
pitals in Africa region and seven in Western Pacific region (compared to 33 in Europe region),
lending generalisability to our findings.
Antibiotic stewardship interventions around optimal dosing in children is hampered by
inconsistency and lack of an evidence base. This affects not only prescribing practice, but also
research, as there are no clearly accepted standard international guidelines for comparators in
trials. We can identify no clear rationale for the historical variation in dosing guidance interna-
tionally. There is a clear opportunity for the clinical, scientific and public health communities
to consolidate behind a consistent set of dosing guidelines for practice and future research
PLOS ONE Characterising paediatric antibiotic dosing variation
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priorities. We suggest the relevant organisations that produce widely used antibiotic guidelines
for children have an opportunity to harmonise international guidance for antibiotic dosing in
children based on best available evidence [1] and knowledge of current practice presented
here.
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